Article
Applied Clinical Trials
Early Phase CRO Chosen for Cell-Based Therapy Diabetes Trial
Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation
Chula Vista, Calif.-based early phase CRO will undertake DiaVacs, a biotech company testing a Type I diabetes therapy in Phase Ib/IIa trials. The double-blind, placebo-controlled study will begin by first enrolling 10 subjects who are at least 18 years of age with newly diagnosed Type I diabetes (< 6 months from diagnosis). The 15-month study commitment will have the study participants visiting the Profil facility to test DiaVacs proprietary cell-based therapy. Profil specializes in diabetes and obesity trials.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
